Agios Pharmaceuticals Inc (NASDAQ:AGIO) has received a consensus recommendation of “Buy” from the fifteen analysts that are presently covering the company. Four investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $63.74.
Several equities analysts have recently weighed in on the company. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Agios Pharmaceuticals in a research report on Sunday, December 18th. Canaccord Genuity set a $90.00 price target on Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, December 18th. Needham & Company LLC restated a “buy” rating and set a $60.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, December 7th. Janney Montgomery Scott upgraded Agios Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $57.00 target price for the company in a research report on Thursday, February 16th. Finally, Cowen and Company restated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Thursday, February 16th.
In other Agios Pharmaceuticals news, Director Robert Nelsen sold 40,599 shares of Agios Pharmaceuticals stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $50.84, for a total transaction of $2,064,053.16. Following the completion of the sale, the director now owns 109,230 shares of the company’s stock, valued at $5,553,253.20. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $50.01, for a total value of $300,060.00. Following the sale, the chief executive officer now directly owns 6,000 shares of the company’s stock, valued at approximately $300,060. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 425,045 shares of company stock valued at $21,045,561. 10.55% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of AGIO. DIAM Co. Ltd. raised its stake in shares of Agios Pharmaceuticals by 110.8% in the third quarter. DIAM Co. Ltd. now owns 71,030 shares of the biopharmaceutical company’s stock valued at $3,680,000 after buying an additional 37,336 shares during the period. Columbus Circle Investors purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $15,999,000. Monashee Investment Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the third quarter valued at about $5,282,000. BlackRock Group LTD raised its stake in shares of Agios Pharmaceuticals by 52.2% in the third quarter. BlackRock Group LTD now owns 199,561 shares of the biopharmaceutical company’s stock valued at $10,540,000 after buying an additional 68,435 shares during the period. Finally, BB Biotech AG raised its stake in shares of Agios Pharmaceuticals by 12.1% in the third quarter. BB Biotech AG now owns 2,649,528 shares of the biopharmaceutical company’s stock valued at $139,948,000 after buying an additional 286,207 shares during the period. 88.79% of the stock is owned by hedge funds and other institutional investors.
Agios Pharmaceuticals (NASDAQ:AGIO) opened at 56.16 on Thursday. The firm has a 50-day moving average price of $48.31 and a 200 day moving average price of $49.22. The company’s market capitalization is $2.37 billion. Agios Pharmaceuticals has a 52-week low of $34.31 and a 52-week high of $67.74.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 16th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.51) by $0.17. The company earned $22.65 million during the quarter, compared to analysts’ expectations of $10.89 million. Agios Pharmaceuticals had a negative return on equity of 53.39% and a negative net margin of 341.56%. The firm’s quarterly revenue was up 264.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.08) earnings per share. On average, analysts predict that Agios Pharmaceuticals will post ($7.31) earnings per share for the current fiscal year.
Your IP Address:
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.